TrakCel Names Akshay Peer Senior VP

TrakCel, a provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, appointed Akshay Peer senior vice president product. Peer returns to TrakCel from Bluecrux, having gained nearly three years of insight into the challenges facing the CGT industry, specifically solutions designed to refine the scheduling of manufacturing capacity.

TrakCel believes Peer’s technological academic background paired with experience gained during his time at Bluecrux will play a major contribution to allowing TrakCel to support future growth of both its own product roadmap and its delivery to the wider CGT industry. Peer’s immediate focus will be to strengthen industry insights, supporting the product team to enhance the development of specific product features. This will involve a contribution to the definition of TrakCel’s roadmap for OCELLOS based on customer and wider industry requirements.

“Akshay developed world-leading chain of custody and chain of identity expertise, as well as detailed knowledge of cellular orchestration processes in his eight years as co-founder at TrakCel,” said Fiona Withey, CEO, TrakCel. “Following TrakCel’s growth into what is now the leading cellular orchestration systems company globally, Akshay left to further broaden his experience of the CGT supply chain from a different perspective. In the meantime, TrakCel developed its next generation CGT orchestration product OCELLOS. TrakCel has now regained a co-founder who embodies the knowledge and passion for the cell orchestration industry, combining it with firsthand recent experience of meeting CGT manufacturing challenges globally. He is therefore able to act as an essential ambassador between the requirements of the CGT industry and the delivery of products to meet those needs.”

Peer said, “Having been part of the founding team of TrakCel in 2012, I have seen the company established as the leading provider of cellular orchestration systems. This has had material effects across the entire CGT sector, as well as the deployment of therapies to patients. Having now completed a set of new challenges from Bluecrux, this has given me a fresh perspective and crucial insight into the main challenges faced during scale-up, directly from a different industry player. This has built on my experience at the forefront of cellular orchestration and my expertise in Chain of Identity and Custody solutions.  I now am able to make an even bigger impact within TrakCel to continue the development of vital products including OCELLOS that will, in turn, make a significant improvement to the delivery of therapies to patients.”